We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening ... Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. Show more
Ask ADVFN Intelligence (AI)
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced...
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced...
– Study Demonstrates that RLYB212 Rapidly Clears HPA-1a Positive Platelets, an Essential Step in Preventing Alloimmunization and FNAIT – – Rallybio On Track to Initiate RLYB212 Phase 2 Dose...
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today...
– On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 4Q 2024 – – $88.6 Million in Cash, Cash Equivalents, and Marketable Securities as of...
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today...
– First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries – – Topline Results Suggest a Significant Increase in the Number of Pregnancies at Higher Risk...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 0.909090909091 | 1.1 | 1.15 | 1.09 | 61381 | 1.10651441 | CS |
| 4 | -0.03 | -2.63157894737 | 1.14 | 1.25 | 1.09 | 74264 | 1.13158785 | CS |
| 12 | -0.29 | -20.7142857143 | 1.4 | 1.6 | 1.09 | 175668 | 1.31086609 | CS |
| 26 | -0.72 | -39.3442622951 | 1.83 | 3.46 | 1.09 | 868188 | 2.61263695 | CS |
| 52 | -4.28 | -79.4063079777 | 5.39 | 5.96 | 1.09 | 515903 | 2.54824038 | CS |
| 156 | -10.3 | -90.2716914987 | 11.41 | 21 | 1.09 | 228961 | 4.12713582 | CS |
| 260 | -13.81 | -92.5603217158 | 14.92 | 25.78 | 1.09 | 227146 | 4.50647031 | CS |
Monksdream
1 week ago
Monksdream
2 months ago
Monksdream
4 months ago
glenn1919
5 months ago
Monksdream
5 months ago
glenn1919
5 months ago
Monksdream
7 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
